News | August 02, 2022
Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
